<DOC>
	<DOCNO>NCT02340780</DOCNO>
	<brief_summary>The purpose study find effect new drug , buparlisib , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Buparlisib Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Buparlisib show shrink tumour animal . It study people seem promise clear offer well result standard treatment . The standard usual treatment disease chemotherapy , target therapy radiation , either alone combination .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Previously document CLL recurrent relapse previous therapy require treatment Age ≥ 18 year ECOG Performance Status score 0 , 1 2 Patients must life expectancy least 12 week . Those previously complete curative treatment malignancy CLL eligible Patients must least ONE : Lymphocyte count ≥ 10 x 10^9/L OR least one pathologically enlarge lymph node ( ≥ 2 x 2 cm ) CT scan Previous therapy : Patients must receive least 1 prior systemic treatment regimen ( single agent combination therapy ) . There upper limit number prior regimen . Patients receive prior autologous allogeneic stem cell transplantation eligible . Patients must recover ( ≤ grade 2 ) reversible toxicity relate prior systemic therapy , adequate washout prior chemotherapy investigational agent define long : two week standard cycle length prior regimen ( e.g . 28 day FCR ) 5 halflives investigational drug Not permit : • prior treatment buparlisib ( BKM120 ) Patients may radiation , provide minimum 21 day elapse prior enrollment . Patients must recover acute toxic effect radiation prior registration Previous surgery permit provide wound heal occur least 14 day elapse surgery major Absolute neutrophil count ( ANC ) : ≥ 1.0 x 10^9/L Platelets ≥ 50/min x 10^9/L 5 day since last transfusion Creatinine clearance* ≥ 50 mL/min Bilirubin** ≤ 1.5 x upper normal limit ( UNL ) Alanine aminotransferase ( AST ) aspartate aminotransferase ( ALT ) ≤ 1.5 x UNL ≤ 3 x UNL hepatic involvement CLL Potassium calcium Within normal limit laboratory ( supplementation permit ) Glucose ( fast ) &lt; 7.8 mmol/L ( AND HbA1c ≤ 8 % diabetic ) * Creatinine clearance calculate CockcroftGault formula 24 hour urine measurement : Females : GFR = 1.04 x ( 140age ) x weight kg serum creatinine μmol/L Males : GFR = 1.23 x ( 140age ) x weight kg serum creatinine μmol/L ** Direct patient know Gilbert 's syndrome Patient consent must obtain accord local Institutional and/or University Human Experimentation Committee requirement Patients must accessible treatment follow . Patients register trial must treat follow participate centre In accordance CCTG policy , protocol treatment begin within 2 work day patient registration Progression high grade lymphoma ( Richter 's transformation ) myelodysplasia Patients know hypersensitivity study drug excipients The following exclusion enrolment study : Pregnant lactate woman . ( N.B . All woman childbearing potential must negative serum urine pregnancy test within 7 day prior registration ) . Men woman childbearing potential agree use adequate contraception : prior study entry ; take buparlisib completion study therapy 12 week men 4 week woman . Serious illness medical condition would permit patient manage accord protocol , include , limited : 1. active uncontrolled serious infection ( viral , bacterial fungal ) ; 2. pulmonary disease require oxygen ; 3. know HIV infection immune deficiency disorder ( except CLL ) ; 4. uncontrolled autoimmune hemolytic anemia ( AIHA ) autoimmune thrombocytopenia ( ITP ) 5. acute chronic pancreatitis Uncontrolled significant cardiovascular disease include : Myocardial infarction within 12 month Uncontrolled angina within 6 month Clinically significant congestive heart failure ( eligible control LVEF ≥ 50 % ) Stroke , TIA ischemic event within 12 month Severe cardiac valve dysfunction Left ventricular ejection fraction &lt; 50 % ( require symptom suggestive history cardiovascular disease ) Uncontrolled hypertension Patient follow mood disorder : Medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) Score ≥ 12 PHQ9 questionnaire Score ≥ 15 GAD7 mood scale ≥ CTCAE grade 3 anxiety Patient select positive response ' 1,2,3 ' question 9 ( suicidal ideation ) PHQ9 questionnaire Patients receive prior buparlisib ( BKM120 ) . Patients impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption buparlisib ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients unable swallow capsule Patients strong CYP3A inhibitors/inducers therapeutic dos warfarinlike anticoagulant ( must discontinue &gt; 7 day prior day 1 ) . Patients may receive low molecular weight heparin indicate . See Appendix VII list prohibit medication . Patients drug know risk induce Torsades de Pointes Patients receive high dose steroid therapy another immunosuppressive agent . Note : Topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) allow . Patients stable moderate dose corticosteroid treatment treatment condition CLL ( &lt; dexamethasone 4 mg/day , prednisone 25 mg/day ) least 14 day start study treatment eligible . Patients know HIV positivity . Patients know CLL involvement central nervous system . Patients history malignancy , except curatively treat require ongoing therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>